Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H11I3N2O4 |
| Molecular Weight | 627.9402 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C(C)=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=GGGDNPWHMNJRFN-UHFFFAOYSA-N
InChI=1S/C12H11I3N2O4/c1-4(18)16-10-7(13)6(12(20)21)8(14)11(9(10)15)17(3)5(2)19/h1-3H3,(H,16,18)(H,20,21)
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
300 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3375780/ |
2310 mg single, intravenous dose: 2310 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METRIZOIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
250 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3375780/ |
2310 mg single, intravenous dose: 2310 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METRIZOIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
75.1 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3375780/ |
2310 mg single, intravenous dose: 2310 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METRIZOIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3375780/ |
2310 mg single, intravenous dose: 2310 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METRIZOIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Enrichment and analysis of secretory lysosomes from lymphocyte populations. | 2009-07-29 |
|
| Acute renal failure in rats. Interaction between contrast media and temporary renal arterial occlusion. | 1989-05-01 |
|
| Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog. Induction of ventricular fibrillation and decrease of aortic pressure. | 1987 |
|
| ECG changes and arrhythmias induced by ionic and non-ionic contrast media during coronary arteriography in dogs. | 1978-05-01 |
|
| Adverse general reactions to high doses of methylglucamine-based contrast media. | 1974-09 |
|
| Increased ventricular fibrillation during coronary arteriography with a new contrast medium preparation. | 1971-10 |
Sample Use Guides
In Vivo Use Guide
Sources: http://newdruginformation.com/Isopaque_280.htm
0.35 mg/ml; 140.1 mg/ml; 461.8 mg/ml
Route of Administration:
Intravascular
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000010258
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
||
|
WHO-ATC |
V08AA02
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
||
|
NDF-RT |
N0000180185
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
||
|
WHO-VATC |
QV08AA02
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
||
|
NCI_THESAURUS |
C390
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB09346
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
100000085979
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
DTXSID6023311
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
217-761-1
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
C76635
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
1789
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
34847
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
CHEMBL1736
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
1949-45-7
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
m7505
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
2528
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
Metrizoic acid
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
SUB03276MIG
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY | |||
|
CM1N99QR1M
Created by
admin on Mon Mar 31 17:33:54 GMT 2025 , Edited by admin on Mon Mar 31 17:33:54 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)